Literature DB >> 28419506

Neuronal loss, demyelination and volume change in the multiple sclerosis neocortex.

D Carassiti1, D R Altmann2, N Petrova1, B Pakkenberg3, F Scaravilli1, K Schmierer1,4.   

Abstract

AIMS: Indices of brain volume [grey matter, white matter (WM), lesions] are being used as outcomes in clinical trials of patients with multiple sclerosis (MS). We investigated the relationship between cortical volume, the number of neocortical neurons estimated using stereology and demyelination.
METHODS: Nine MS and seven control hemispheres were dissected into coronal slices. On sections stained for Giemsa, the cortex was outlined and optical disectors applied using systematic uniform random sampling. Neurons were counted using an oil immersion objective (× 60) following stereological principles. Grey and WM demyelination was outlined on myelin basic protein immunostained sections, and expressed as percentages of cortex and WM respectively.
RESULTS: In MS, the mean number of neurons was 14.9 ± 1.9 billion vs. 24.4 ± 2.4 billion in controls (P < 0.011), a 39% difference. The density of neurons was smaller by 28% (P < 0.001) and cortical volume by 26% (P = 0.1). Strong association was detected between number of neurons and cortical volume (P < 0.0001). Demyelination affected 40 ± 13% of the MS neocortex and 9 ± 12% of the WM, however, neither correlated with neuronal loss. Only weak association was detected between number of neurons and WM volume.
CONCLUSION: Neocortical neuronal loss in MS is massive and strongly predicted by cortical volume. Cortical volume decline detected in vivo may be similarly indicative of neuronal loss. Lack of association between neuronal density and demyelination suggests these features are partially independent, at least in chronic MS.
© 2017 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd on behalf of British Neuropathological Society.

Entities:  

Keywords:  cortical pathology; neuronal loss; progressive multiple sclerosis

Mesh:

Year:  2017        PMID: 28419506     DOI: 10.1111/nan.12405

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  23 in total

Review 1.  The immunology of multiple sclerosis.

Authors:  Kathrine E Attfield; Lise Torp Jensen; Max Kaufmann; Manuel A Friese; Lars Fugger
Journal:  Nat Rev Immunol       Date:  2022-05-04       Impact factor: 53.106

Review 2.  Sphingolipids in neurodegeneration (with focus on ceramide and S1P).

Authors:  Guanghu Wang; Erhard Bieberich
Journal:  Adv Biol Regul       Date:  2018-09-22

3.  Long-standing multiple sclerosis neurodegeneration: volumetric magnetic resonance imaging comparison to Parkinson's disease, mild cognitive impairment, Alzheimer's disease, and elderly healthy controls.

Authors:  Dejan Jakimovski; Niels Bergsland; Michael G Dwyer; Jesper Hagemeier; Deepa P Ramasamy; Kinga Szigeti; Thomas Guttuso; David Lichter; David Hojnacki; Bianca Weinstock-Guttman; Ralph H B Benedict; Robert Zivadinov
Journal:  Neurobiol Aging       Date:  2020-02-08       Impact factor: 4.673

4.  Guggulsterone ameliorates ethidium bromide-induced experimental model of multiple sclerosis via restoration of behavioral, molecular, neurochemical and morphological alterations in rat brain.

Authors:  Nitish Kumar; Nidhi Sharma; Rishabh Khera; Ria Gupta; Sidharth Mehan
Journal:  Metab Brain Dis       Date:  2021-02-26       Impact factor: 3.584

5.  Cortical degeneration detected by neurite orientation dispersion and density imaging in chronic lacunar infarcts.

Authors:  Hui Hong; Xinfeng Yu; Ruiting Zhang; Yeerfan Jiaerken; Shuyue Wang; Xiao Luo; Min Lou; Peiyu Huang; Minming Zhang
Journal:  Quant Imaging Med Surg       Date:  2021-05

6.  Stereological Investigation of Regional Brain Volumes after Acute and Chronic Cuprizone-Induced Demyelination.

Authors:  Tanja Hochstrasser; Sebastian Rühling; Kerstin Hecher; Kai H Fabisch; Uta Chrzanowski; Matthias Brendel; Florian Eckenweber; Christian Sacher; Christoph Schmitz; Markus Kipp
Journal:  Cells       Date:  2019-09-03       Impact factor: 6.600

7.  Applying causal models to explore the mechanism of action of simvastatin in progressive multiple sclerosis.

Authors:  Arman Eshaghi; Rogier A Kievit; Ferran Prados; Carole H Sudre; Jennifer Nicholas; M Jorge Cardoso; Dennis Chan; Richard Nicholas; Sebastien Ourselin; John Greenwood; Alan J Thompson; Daniel C Alexander; Frederik Barkhof; Jeremy Chataway; Olga Ciccarelli
Journal:  Proc Natl Acad Sci U S A       Date:  2019-05-09       Impact factor: 11.205

8.  Single-Cell Microwell Platform Reveals Circulating Neural Cells as a Clinical Indicator for Patients with Blood-Brain Barrier Breakdown.

Authors:  Yu Zhang; Antony R Warden; Khan Zara Ahmad; Yanlei Liu; Xijun He; Minqiao Zheng; Xinlong Huo; Xiao Zhi; Yuqing Ke; Hongxia Li; Sijia Yan; Wenqiong Su; Deng Cai; Xianting Ding
Journal:  Research (Wash D C)       Date:  2021-07-08

Review 9.  The Cuprizone Model: Dos and Do Nots.

Authors:  Jiangshan Zhan; Teresa Mann; Sarah Joost; Newshan Behrangi; Marcus Frank; Markus Kipp
Journal:  Cells       Date:  2020-03-31       Impact factor: 6.600

10.  Time matters in multiple sclerosis: can early treatment and long-term follow-up ensure everyone benefits from the latest advances in multiple sclerosis?

Authors:  João J Cerqueira; D Alastair S Compston; Ruth Geraldes; Mario M Rosa; Klaus Schmierer; Alan Thompson; Michela Tinelli; Jacqueline Palace
Journal:  J Neurol Neurosurg Psychiatry       Date:  2018-04-04       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.